Catalyst Pharma Sale Draws Investor Lawsuit Probe – $31.50 Bid Under Scrutiny

What happened

Catalyst Pharmaceuticals has agreed to be acquired by Angelini Pharma for $31.50 per share in cash. Law firm Kahn Swick & Foti is investigating whether the consideration and process adequately value the company. The master report valued Catalyst's intrinsic worth at over $108 per share based on its durable rare-disease portfolio and strong cash flows. The acquisition price represents a roughly 47% premium to the prior close but still far below the report's DCF valuation. Shareholders may question if the board is leaving significant value on the table, especially given the company's recent $200M buyback authorization and improving fundamentals.

Implication

For investors, the investigation highlights a gap between market price and fundamental value. If the acquisition proceeds at $31.50, it may limit upside for current holders. However, the probe could pressure the board to seek a higher price or terminate the deal. Long-term holders who bought at lower valuations may consider selling into the offer if they believe no better bid emerges. Those who trust the master report's intrinsic value may argue the company is worth more and could be better off independent. The outcome of the investigation and any shareholder litigation will be key.

Thesis delta

The proposed sale at $31.50 contradicts the master report's BUY thesis based on a DCF intrinsic value of $108.3. This creates a conflict: either the market is mispricing the acquisition, or the DCF assumptions are too optimistic. The investigation underscores that the bid may not reflect full long-term value, potentially pushing the thesis toward 'sell into the bid' or 'hold out for more'.